Stockreport

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strateg [Read more]